| 24.34 -0.58 (-2.33%) | 09-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 31.38 | 1-year : | 36.65 |
| Resists | First : | 26.87 | Second : | 31.38 |
| Pivot price | 25.3 |
|||
| Supports | First : | 23.69 | Second : | 21.73 |
| MAs | MA(5) : | 25.41 |
MA(20) : | 25.17 |
| MA(100) : | 19  |
MA(250) : | 17.01 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 31.4 |
D(3) : | 52.7 |
| RSI | RSI(14): 49.3 |
|||
| 52-week | High : | 26.87 | Low : | 12 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ADPT ] has closed above bottom band by 14.7%. Bollinger Bands are 25.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.05 - 25.21 | 25.21 - 25.32 |
| Low: | 23.53 - 23.72 | 23.72 - 23.85 |
| Close: | 24.66 - 24.95 | 24.95 - 25.15 |
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Tue, 01 Sep 2026
Adaptive Biotechnologies Corp (ADPT) Peer Comparison – Compare with Others - Value Research
Sun, 30 Aug 2026
Adaptive Biotechnologies Corp (ADPT) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Sat, 29 Aug 2026
Director Katey Owen Sells 9,615 Shares of Adaptive Biotechnologies Corp (ADPT) - GuruFocus
Fri, 28 Aug 2026
Adaptive Biotechnologies director Owen sells $249,990 in stock. - Investing.com
Fri, 28 Aug 2026
Adaptive Biotechnologies (NASDAQ: ADPT) director sells at $26, keeps 78,639 - Stock Titan
Fri, 28 Aug 2026
Adaptive Biotechnologies (ADPT), Why Is It Getting Fresh Attention Now? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 160 (M) |
| Shares Float | 125 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 99.2 (%) |
| Shares Short | 12,490 (K) |
| Shares Short P.Month | 11,350 (K) |
| EPS | -0.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.89 |
| Profit Margin | -20.8 % |
| Operating Margin | -22.1 % |
| Return on Assets (ttm) | -4.2 % |
| Return on Equity (ttm) | -38.8 % |
| Qtrly Rev. Growth | 21.5 % |
| Gross Profit (p.s.) | 0.9 |
| Sales Per Share | 1.93 |
| EBITDA (p.s.) | -0.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | 19 (M) |
| PE Ratio | -60.97 |
| PEG Ratio | 0 |
| Price to Book value | 27.09 |
| Price to Sales | 12.63 |
| Price to Cash Flow | -185.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|